10:46 AM EDT, 05/14/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Tuesday its partner Everest Medicines is offering Nefecon in China.

China's National Medical Products Administration granted conditional approval for Nefecon in November 2023 as a treatment for IgA nephropathy, the progressive autoimmune disease, the company said. Nefecon is also approved in Macau, Hong Kong and Singapore, Calliditas Therapeutics ( CALT ) said.

Shares of Calliditas Therapeutics ( CALT ) rose 3.7% in recent trading Tuesday.

Price: 22.58, Change: +0.80, Percent Change: +3.67